

LISTING OF CLAIMS:

Claims 1-20 (canceled)

Claim 21 (Currently amended): A method of predicting an increased risk for prostate cancer, comprising:

measuring the concentration of IGF-I in a body fluid from each of a reference group of healthy individuals without prostate cancer to establish a reference level;

measuring the concentration of IGF-I in a body fluid from ~~an~~ a healthy individual outside the reference group; and

comparing the concentration of IGF-I in the healthy individual outside the reference group to the reference level, wherein an elevated concentration of IGF-I above the reference level indicates an increased risk for prostate cancer.

Claim 22 (Previously presented) The method of claim 21, wherein the body fluid is blood, plasma, or serum.

Claim 23 (Previously presented) The method of claim 21, wherein the IGF-I is total IGF-I, free IGF-I, or complexed IGF-I.

Claim 24 (Previously presented) A method of predicting an increased risk for prostate cancer, comprising:

establishing a reference level of the concentration of IGF-I in a body fluid from healthy individuals without prostate cancer;

measuring the concentration of IGF-I in a body fluid from ~~an~~ healthy individual outside the reference group; and

comparing the concentration of IGF-I in the healthy individual outside the reference group to the reference level, wherein an elevated concentration of IGF-I above the reference level indicates an increased risk for prostate cancer.

Claim 25 (Previously presented) The method of claim 24, wherein the body fluid is blood, plasma, or serum.

Claim 26 (Previously presented) The method of claim 24, wherein the IGF-I is total IGF-I, free IGF-I or complexed IGF-I.

Claim 27 (Previously presented) A method of predicting an increased risk for prostate cancer, comprising:

measuring the concentration of IGF-I in a body fluid from ~~an~~ a healthy individual without prostate cancer; and

comparing the concentration of IGF-I in the individual to a reference level of the concentration of IGF-I in a body fluid from healthy individuals without prostate cancer, wherein an elevated concentration of IGF-I above the reference level indicates an increased risk for prostate cancer.